leukodopachrome: proposed metabolite in pathway from tyrosine to dopachrome; RN given refers to (S)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
leucodopachrome : Indoline substituted with hydroxy groups at C-5 and -6 and a carboxy group at C-2, and with S stereochemistry at C-2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 161255 |
| CHEBI ID | 60872 |
| SCHEMBL ID | 10276636 |
| MeSH ID | M0107903 |
| Synonym |
|---|
| (s)-5,6-dihydroxyindoline-2-carboxylic acid |
| leukodopachrome |
| cyclodopa |
| l-2-carboxy-2,3-dihydro-5,6-dihydroxyindole |
| (s)-2-carboxy-5,6-dihydroxyindoline |
| CHEBI:60872 |
| leucodopachrome |
| cyclo-dopa |
| 18766-67-1 |
| 2-carboxy-2,3-dihydro-5,6-dihydroxyindole |
| C05604 |
| (2s)-5,6-dihydroxy-2,3-dihydro-1h-indole-2-carboxylic acid |
| 2,3-dihydro-5,6-dihydroxyindole-2-carboxylate |
| 1h-indole-2-carboxylic acid, 2,3-dihydro-5,6-dihydroxy-, (s)- |
| SCHEMBL10276636 |
| DTXSID80172072 |
| leucodopachrome hydrochloride |
| Q15491505 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| indoles | Any compound containing an indole skeleton. |
| hydroxy monocarboxylic acid | Any monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism | 1496 | 1108 |
| Amino acid and derivative metabolism | 250 | 260 |
| Melanin biosynthesis | 5 | 16 |
| Tyrosine Metabolism | 16 | 57 |
| Alkaptonuria | 16 | 57 |
| Hawkinsinuria | 16 | 57 |
| Tyrosinemia Type I | 16 | 57 |
| Disulfiram Action Pathway | 23 | 66 |
| Tyrosinemia, Transient, of the Newborn | 16 | 57 |
| Dopamine beta-Hydroxylase Deficiency | 16 | 57 |
| Monoamine Oxidase-A Deficiency (MAO-A) | 16 | 57 |
| L-dopa and L-dopachrome biosynthesis | 0 | 8 |
| betacyanin biosynthesis | 1 | 17 |
| superpathway of betalain biosynthesis | 2 | 41 |
| Dopamine metabolism | 0 | 32 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||